Sinopharm Medical Supply Chain Files IPO Prospectus for Innovative Payment Model and Full-Cycle Surgical Platform for Critically Ill Patients in Grassroots China

"Difficulty in accessing medical care" has always been an unavoidable topic in China's healthcare system. However, "seeking medical care" is not a one-way event; it encompasses the entire process from illness to recovery. Among these stages, surgery is undoubtedly the most critical and challenging component, especially forCardiovascular, Cerebrovascular, OncologyFor major and critical surgeries, the process is often more “arduous.”

Although there are many unmet market demands, compared toTeleconsultation, Outpatient Care, Medication, InsuranceWhile high-frequency medical sectors have already reached maturity, the field of critical care surgery remains in an exploratory stage, with a relatively small number of companies operating in this niche and overall development lagging behind.

This is not without reason. Compared to other segments of healthcare, the surgical services sector has higher barriers to entry,On one hand, it is highly specialized., companies need to have a certain level of knowledge reserve in various disciplines,On the other hand, there are stringent requirements for resource integration capabilities., enterprises need to accumulate sufficient resources across various service touchpoints, including hospitals, physicians, medical devices and pharmaceuticals, and insurance. However, innovation in the surgical field is of critical importance and necessity. First, the quality of surgical procedures directly determines patients’ therapeutic outcomes and even their survival. Second, surgical expenses account for a significant proportion of total healthcare costs, ranging from 30% to 60%. If substantial improvements can be made in the payment segment, it would greatly reduce the risk of patients falling into poverty due to illness.

Therefore, the field of critical care surgery urgently needs “warriors” who dare to face the storm head-on, and Sinopharm Supply Chain is one of them.

The establishment of Sinopharm’s medical supply chain was not a whim, but rather based on a comprehensive underlying logic. The company’s founderZhang JingnanHe explained to VCBeat, “The ratio of doctors to patients has long been a persistent challenge in the field of critical care surgery. As this issue lies at the very beginning of the surgical journey, version 1.0 of Sinopharm’s medical supply chain initiative focused on building a doctor–patient brand centered on critical care surgeries, establishing an efficient bridge between physicians and patients. To date, it has taken the lead in launching surgical service platforms in cardiology, oncology, and neurology. Version 2.0, against the backdrop of China’s national volume-based procurement policy, redefines the value of surgical medical services by adopting a patient-centric approach, assisting patients in negotiating with suppliers to provide the most cost-effective surgical services. Version 3.0 introduces innovative payment models, with Sinopharm’s medical supply chain acting as the patients’ ‘agent’ to negotiate with insurance companies, striving to secure the most inclusive prices for patients and positioning itself as a leader in reforms on the healthcare payment side.”

Following this planned path, Sinopharm's medical supply chain has precisely laid out its various services.

First is to improve the accessibility of medical services for patients.Through the digital platform, for the contractedNearly 2,000 surgical physicians from Grade A tertiary hospitalsConduct visual assessments and precisely match patients with the industry’s top surgeons based on their actual needs, enabling efficient access to elite surgical expertise. This service model not only provides substantial convenience for patients in their treatment journey but also increases “transparent income” for surgeons, creating a true win-win scenario.

Next is to enhance support on the supply side.Sinopharm Medical Supply Chain has currently partnered withGE, Philips, Johnson & Johnson, Medtronic, Boston ScientificThe company has signed cooperation agreements with leading medical device manufacturers, offering a comprehensive product portfolio that covers three major specialties: cardiovascular, cerebrovascular, and oncology. With a patient-centric approach, the enterprise will negotiate prices with service providers to ensure overall treatment quality while reducing out-of-pocket expenses, thereby delivering high-value surgical services to patients.

Finally, establish innovative payment models.For the vast majority of patients, surgical expenses have always been a “confusing account,” with overall consumption accounting for a high proportion, ranging from 30% to 60%. Based on this, Sinopharm Medical Supply Chain will take on itsPatient “Agent”its role by collaborating with insurance companies such as Ping An Insurance and Everbright Insurance, leveraging negotiated pricing to reduce surgical costs for patients while ensuring they have a clear understanding of their out-of-pocket expenses.

Sinopharm Medical Supply Chain has primarily focused on grassroots patients, leveraging the Chinese Volunteer Doctors Alliance and its in-house team for market promotion and strategic deployment. To date, it has served over 1,000 patients in a short period, receiving positive overall market feedback, and plans to further expand its service boundaries in the future.

From Concept to Execution: What Is the Core Strength Empowering Sinopharm’s Medical Supply Chain to Enhance Patient Convenience and Ensure Sustainable Growth?

First, it has a "high-precision and advanced" core team.Zhang Jingnan, the company’s founder, has held senior management positions—including Managing Director, Business Unit General Manager, and Director—at leading healthcare companies such as Sinopharm Group, Cardinal Health, Smiths Medical, and Johnson & Johnson. In addition to building extensive industry experience, he has accumulated substantial industry resources. Furthermore, other core team members of the company also come from globally renowned enterprises such as Johnson & Johnson, Medtronic, and Roche Pharmaceuticals, where they previously held key roles at the director or regional manager level. They possess exceptional professional capabilities and a profound understanding of the industry.

Second, it possesses robust and extensive hospital and physician resources.To date, Sinopharm’s medical supply chain has signed agreements with 2,000 surgeons from Grade A tertiary hospitals. This team of physicians brings extensive surgical experience and is capable of delivering high-quality surgical services to patients. On the hospital side, Sinopharm’s medical supply chain currently covers nearly 4,000 county-level primary care hospitals, accounting for 67% of the total, thereby adequately addressing the substantial unmet demand for medical resources.

Third, it possesses a stable supply chain.In addition to hospital and physician resources, Sinopharm’s medical supply chain has also established a robust supply network connecting medical device manufacturers and insurance companies. Leveraging its accumulated resources, Sinopharm’s medical supply chain has forged partnerships with GE, Medtronic, Johnson & Johnson, Philips, and Boston Scientific, building a vertical, one-stop service platform focused on cardiovascular care and critical oncology patients. On the insurance front, Sinopharm’s medical supply chain has signed long-term cooperation agreements with Ping An Insurance and Everbright Insurance. Negotiations are actively underway with China Life Insurance, China Taiping Insurance, and People’s Insurance Company of China (PICC), with potential signings expected in the future to strengthen the company’s service capabilities in the insurance sector.

Fourth, a full-cycle surgical service platform has been established for patients.From the initial consultation to postoperative rehabilitation, Sinopharm Medical Supply Chain deeply integrates its services into every specialized segment. By introducing professional service capabilities and leveraging top-tier surgical resources, it has established an integrated surgical service platform for patients. This approach not only ensures surgical quality but also significantly reduces high surgical costs, making procedures more efficient and cost-effective.

According to relevant research surveys,China's current number of cardiovascular disease patients has reached 330 million., which means that approximately one-quarter of China's population suffers from cardiovascular and cerebrovascular diseases. Among them, 30% require surgical intervention, amounting to nearly 100 million patient visits, indicating a substantial market potential.

Based on this, Sinopharm Supply Chain is already laying the groundwork for the future.On one hand, it involves introducing more top-tier resources, while enhancing corporate service capabilities, continuously exploring other underserved areas in critical care surgery;On the other hand, we will strengthen our marketing efforts., by leveraging its in-house marketing team and extensive resource advantages, to extend service coverage to a broader population in need.

The objectives are clear, but their actual realization requires reinforcement and supplementation across multiple stages. Zhang Jingnan told VCBeat, “For Sinopharm’s medical supply chain, the most pressing need at present isSupport of Internet Operation Thinking, which is mainly reflected in its internet-based market operation capabilities and specialized talent in insurtech. In addition,The injection of capital is also a critical need for enterprises at the current stage., on the one hand, to better support the rapid advancement of the company’s various business segments; on the other hand, to optimize its corporate structure and governance, while fostering synergistic collaboration with strategic investors to jointly drive the continuous development of the enterprise and the entire critical care surgery sector. We have engaged Reynold Lemkins China (Rui Kai China), which possesses extensive experience in international capital markets, as our financial advisor to work closely with us on corporate restructuring, capital and strategic planning, and investment introduction.”

Compared with other medical business segments, critical care surgery can be regarded as an innovative field. On one hand, there are few enterprises in this track; on the other hand, the lack of leading companies to drive development means the industry as a whole is still in an exploratory stage. However, its market potential is enormous and widely needed by society. Therefore, this sector is poised for significant growth in the future, and Sinopharm Supply Chain Management Co., Ltd., committed to becoming China’s largest surgeon-patient surgical platform, has already begun its efforts.